Harousseau JL - Search Results

1

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.

Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. Bataille R, et al. Among authors: harousseau jl. Haematologica. 2005 May;90(5):706-7. Haematologica. 2005. PMID: 15921396

2

Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF.

Jego G, Avet-Loiseau H, Robillard N, Moreau P, Amiot M, Harousseau J, Pellat-Deceunynck C, Bataille R. Jego G, et al. Leuk Res. 2000 Jul;24(7):627-30. doi: 10.1016/s0145-2126(00)00033-3. Leuk Res. 2000. PMID: 10867139

3

Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule.

Puthier D, Thabard W, Rapp M, Etrillard M, Harousseau J, Bataille R, Amiot M. Puthier D, et al. Br J Haematol. 2001 Feb;112(2):358-63. doi: 10.1046/j.1365-2141.2001.02575.x. Br J Haematol. 2001. PMID: 11167829 Free article.

4

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Moreau P, et al. Among authors: harousseau jl. Blood. 2002 Feb 1;99(3):731-5. doi: 10.1182/blood.v99.3.731. Blood. 2002. PMID: 11806971 Free article. Clinical Trial.

5

CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia.

Chevallier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahé B, Hamidou M, Maisonneuve H, Moreau P, Jardel H, Harousseau JL, Bataille R, Garand R. Chevallier P, et al. Among authors: harousseau jl. Br J Haematol. 2002 Jan;116(1):142-50. doi: 10.1046/j.0007-1048.2001.3205.x. Br J Haematol. 2002. PMID: 11841407 Free article.

6

Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study.

Le Gouill S, Moreau P, Morineau N, Harousseau JL, Milpied N. Le Gouill S, et al. Among authors: harousseau jl. Haematologica. 2002 Mar;87(3):333-4. Haematologica. 2002. PMID: 11869953

7

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R; Intergroupe Francophone du Myélome. Avet-Loiseau H, et al. Among authors: harousseau jl. Blood. 2002 Mar 15;99(6):2185-91. doi: 10.1182/blood.v99.6.2185. Blood. 2002. PMID: 11877296 Free article.

8

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Derenne S, et al. Among authors: harousseau jl. Blood. 2002 Jul 1;100(1):194-9. doi: 10.1182/blood.v100.1.194. Blood. 2002. PMID: 12070027 Free article.

9

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H; Intergroupe Francophone du Myélome. Moreau P, et al. Among authors: harousseau jl. Blood. 2002 Sep 1;100(5):1579-83. doi: 10.1182/blood-2002-03-0749. Blood. 2002. PMID: 12176874 Free article.

10

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T. Yakoub-Agha I, et al. Among authors: harousseau jl. Hematol J. 2002;3(4):185-92. doi: 10.1038/sj.thj.6200175. Hematol J. 2002. PMID: 12189564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

552 results

Search Page

Filters